203 related articles for article (PubMed ID: 12556962)
21. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study.
Spanogle JP; Clarke CA; Aroner S; Swetter SM
J Am Acad Dermatol; 2010 May; 62(5):757-67. PubMed ID: 20223559
[TBL] [Abstract][Full Text] [Related]
22. Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival.
Herr MM; Schonfeld SJ; Dores GM; Withrow DR; Tucker MA; Curtis RE; Morton LM
J Natl Cancer Inst; 2018 Nov; 110(11):1248-1258. PubMed ID: 29659938
[TBL] [Abstract][Full Text] [Related]
23. Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection.
Duberg AS; Nordström M; Törner A; Reichard O; Strauss R; Janzon R; Bäck E; Ekdahl K
Hepatology; 2005 Mar; 41(3):652-9. PubMed ID: 15723449
[TBL] [Abstract][Full Text] [Related]
24. A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapies.
Mishra R; Dima D; Kumar SA; Mian A; Taneja A; Karna R; Caimi PF; Hill BT; Dean R; Jagadeesh D
Hematol Oncol; 2023 Dec; 41(5):884-893. PubMed ID: 37309225
[TBL] [Abstract][Full Text] [Related]
25. Increased risk of chronic lymphocytic leukaemia among cancer survivors in the Netherlands: increased detection, causal factors or both?
van den Broek EC; Liu L; Posthuma EF; Janssen-Heijnen ML; Coebergh JW; Soerjomataram I
Ann Hematol; 2014 Jan; 93(1):157-62. PubMed ID: 24381068
[TBL] [Abstract][Full Text] [Related]
26. Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia.
Cerhan JR; Vachon CM; Habermann TM; Ansell SM; Witzig TE; Kurtin PJ; Janney CA; Zheng W; Potter JD; Sellers TA; Folsom AR
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1466-71. PubMed ID: 12433728
[TBL] [Abstract][Full Text] [Related]
27. Second cancers in patients with chronic lymphocytic leukemia.
Travis LB; Curtis RE; Hankey BF; Fraumeni JF
J Natl Cancer Inst; 1992 Sep; 84(18):1422-7. PubMed ID: 1512794
[TBL] [Abstract][Full Text] [Related]
28. Skin cancer and non-Hodgkin's lymphoma: examining the link.
Hu S; Federman DG; Ma F; Kirsner RS
Dermatol Surg; 2005 Jan; 31(1):76-82. PubMed ID: 15720100
[TBL] [Abstract][Full Text] [Related]
29. Pregnancy and risk of non-Hodgkin's lymphoma: a prospective study.
Adami HO; Tsaih S; Lambe M; Hsieh C; Adami J; Trichopoulos D; Melbye M; Glimelius B
Int J Cancer; 1997 Jan; 70(2):155-8. PubMed ID: 9009153
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous malignancies in chronic lymphocytic leukemia.
Zilberg C; Ferguson AL; Lyons JG; Gupta R; Fuller SJ; Damian DL
J Dermatol; 2024 Mar; 51(3):353-364. PubMed ID: 38291978
[TBL] [Abstract][Full Text] [Related]
31. Screening for second malignancies in mycosis fungoides: non-Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer and melanoma.
Goyal A; O'Leary D; Goyal K; Rubin N; Janakiram M
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1821-1829. PubMed ID: 34013554
[TBL] [Abstract][Full Text] [Related]
32. Melanoma and CLL co-occurrence and survival: role of KC history.
Zhao Y; Amorrortu RP; Stewart SC; Ghia KM; Williams VL; Sondak VK; Tsai KY; Pinilla-Ibarz J; Chavez JC; Rollison DE
BMC Cancer; 2023 Nov; 23(1):1084. PubMed ID: 37946198
[TBL] [Abstract][Full Text] [Related]
33. The association between malignant melanoma and noncutaneous malignancies.
Wu YH; Kim GH; Wagner JD; Hood AF; Chuang TY
Int J Dermatol; 2006 May; 45(5):529-34. PubMed ID: 16700785
[TBL] [Abstract][Full Text] [Related]
34. Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia.
Brennan P; Coates M; Armstrong B; Colin D; Boffetta P
Br J Cancer; 2000 Apr; 82(7):1344-7. PubMed ID: 10755412
[TBL] [Abstract][Full Text] [Related]
35. Non-melanoma skin cancer may be a marker of poor prognosis in patients with non-Hodgkin's lymphoma.
Hjalgrim H; Frisch M; Storm HH; Glimelius B; Pedersen JB; Melbye M
Int J Cancer; 2000 Mar; 85(5):639-42. PubMed ID: 10699942
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological characteristics of individuals with coexisting melanoma and chronic lymphocytic leukaemia: a multicentre cohort study.
Fisher RM; Ji-Xu A; Abbott R; Basu T; Brown A; Foley C; Glen C; Gupta G; Hasan Z; Ismail F; Khalid A; Khoo ABS; Koumaki D; Lally A; Lear JT; McGrath EJ; McKenna K; Milligan A; Mulholland O; Tasker F; Harwood CA; Proby CM; Matin RN
Clin Exp Dermatol; 2022 Nov; 47(11):1976-1981. PubMed ID: 35801421
[TBL] [Abstract][Full Text] [Related]
37. Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes.
Herr MM; Schonfeld SJ; Dores GM; Engels EA; Tucker MA; Curtis RE; Morton LM
Blood Adv; 2019 Jul; 3(13):1961-1969. PubMed ID: 31262739
[TBL] [Abstract][Full Text] [Related]
38. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
39. Lymphoma-associated skin cancer: incidence, natural history, and clinical management.
Brewer JD; Habermann TM; Shanafelt TD
Int J Dermatol; 2014 Mar; 53(3):267-74. PubMed ID: 24320558
[TBL] [Abstract][Full Text] [Related]
40. Decreased dickkopf-1 levels in chronic lymphocytic leukemia and increased osteopontin levels in non-Hodgkin's lymphoma at initial diagnosis: Could they be playing roles in pathogenesis?
Pamuk GE; Uyanik MS; Pamuk ON; Maden M; Tapan U
Hematology; 2015 Jun; 20(5):267-71. PubMed ID: 25271869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
